SpotLight™

Health screening, simplified

SpotLight™ operates on a single 30-second non-invasive fingertip scan. This innovation improves the accessibility of early stage viral infection and disease screening offered by traditional solutions by eliminating the need for blood/stool samples, harmful radiation and nasal swabs. SpotLight™ offers real-time on-site results with operational simplicity that enables health screening in environments ranging from international airports to small remote community clinics.

Optical Scan

A 30 second fingertip scan captures high-resolution metabolic signals.

AI

ISBRG’s proprietary algorithms map key biometric data points.

Insights

Real-time screening results enable early stage health insights.

Benefits of SpotLight™

  • Non-invasive

    SpotLight™ is a truly non-invasive screening experience, unlike current invasive methods that require a sample of blood, urine, saliva, stool or tissue.

  • Expandable

    SpotLight™ has the ability to respond to emerging health challenges with timely and seamless algorithm uploads without the need for hardware modifications.

  • Real-time Health Data

    SpotLight™ provides immediate results, verses the days or weeks required for private clinics to have blood or stool samples processed by domestic or off-shore labs.

  • No Expiry Date

    SpotLight™ scans are not chemical reagent based, avoiding the cost and logistical challenges arising from expiration dates observed during the COVID-19 pandemic.

  • Low Cost Per Test

    SpotLight™ offers low-cost screening, providing financial relief to overwhelmed inner city and under-staffed rural healthcare systems.

  • Environmentally Friendly

    SpotLight™ eliminates hazardous chemical reagent waste and the environmental risks associated with current health monitoring methods.

Built on real-world evidence

ISBRG possesses one of the most comprehensive optical datasets of its kind. Each scan strengthens our models, enhances precision and accelerates the evolution of non-invasive health screening.

From its first deployment in COVID-19 clinical trials, SpotLight™ demonstrated stronger sensitivity than antigen tests in detecting asymptomatic infection. These results validated our approach and set the foundation for expanding non-invasive health screening to cancer and viral weaponization applications.